Motivation: This survey
is the result of a large study upon related subjects to
adjuvant therapy for multiple sclerosis (MS). It exposes no miracle
cures and the word "adjuvant" should be noted, implying the
need for other therapy (e.g., high dose interferon-beta) as
the primary, more important treatment. In the following pages,
various items are exposed for your survey. The main motivation
for publishing this review in the Internet is to save you
from spending the time I utilized myself: why should other
people start from the beginning again?
Language: It is the English I write without any
editing. For the purpose of being understood, I hope my
writing suffices. The level should be academically and it
should not be considered popular literature. Besides,
literature abstracts can speak for themselves.
Content: (actual/planned/possible)
Last revision:
Comprehensive
terminology and abbreviations (currently missing)
The Jungle
Model,
"good" and "bad" cells & humoral factors (currently
missing)
Factors primarily
acting against destruction of the blood brain barrier:
Glucocorticoids (uncertain,
currently missing)
Matrix-Metalloproteinase-Inhibitors
Minocycline and other old drugs
revisited
Factors
directed
against oxidant destruction:
Amino
acids, vitamins and trace elements
Jan. 25, 2002
Unspecific
immune manipulation
Intravenous immuneglobulins (uncertain, currently
missing)
Glatimer
racemate (Copaxone, Copolymer-1)
Jan. 25, 2002
Oral tolerance (uncertain, currently
missing)
Other approaches
Mercury Clearance and
d-Penicillamin
Jan. 6, 2009
Transforming growth factor beta
Apr. 4, 2001
July 29, 2011
Nov. 7, 2001
Remyelinization (currently missing,
incuding the realistic clinical approach)
Studying the matter
June 10, 2004
MS-Science 2004:
Nihilism and nonethical studies prevail
Feb. 29, 2004
A future MS-register? (natural history of MS)
Are anaesthetists
at particular risk of
developing MS?
Links to other
MS-sources (currently missing)
Conclusion
MS-Therapy
- a holoistic approach
MS-Therapy - an alternative
approach
Nov. 17, 2002
Last revision July 28